RecruitingPhase 1NCT06321250

A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma

Studying Hereditary clear cell renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Jemincare
Principal Investigator
Jun Guo
Peking University Cancer Hospital & Institute
Intervention
JMKX003948(drug)
Enrollment
80 enrolled
Eligibility
18 years · All sexes
Timeline
20242027

Study locations (1)

Collaborators

Zhejiang Hangyu Pharmaceutical Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06321250 on ClinicalTrials.gov

Other trials for Hereditary clear cell renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Hereditary clear cell renal cell carcinoma

← Back to all trials